VivoSeq
Cardiovascular

Congenital Heart Disease

47

Pipeline Programs↗

12

Active Trials↗

23

Companies Involved↗

Congenital Heart Disease is a moderately active landscape with 47 programs across 23 companies. The most active players are AstraZeneca, Sanofi, Orion Corporation, Orion Pharma. 16 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

15/100

Mech. Concentration

7/100

Completion Rate

72/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 2A

Advanz Pharma

2 programs

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical9

Digoxin

Advanz Pharma

Tranexamic Acid

Amring

Bupivacaine

Innocoll

Acetaminophen

Kenvue Brands

Rivaroxaban

Wim Janssens

Phase 15

Topiramate

Wim Janssens

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Ipsc-CL

HeartWorks, Inc.

Ino Administered

The Cleveland Clinic

IV L-Carnitine

University of California, San Francisco

Phase 28

Milrinone

Sanofi

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Spironolactone

Pfizer

Levosimendan

Orion Corporation, Orion Pharma

Palivizumab

Swedish Orphan Biovitrum

Phase 39

Norepinephrine

General Hospital of Ningxia Medical University

Mannitol

B. Braun Medical Inc.

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Allopurinol

Alnylam Pharmaceuticals

Sildenafil

Viatris Specialty LLC

Approved16

Bosentan

Johnson & Johnson

Propofol

Fresenius Kabi Oncology Ltd.

Macitentan

Johnson & Johnson

Dopamine

Pfizer

Treprostinil

United Therapeutics

Analysis

Modality Breakdown

96%

Small molecule

52 of 54 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody24%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed23 · 47%
Recruiting8 · 16%
Unknown status5 · 10%
Withdrawn5 · 10%
Terminated4 · 8%
Not yet recruiting3 · 6%
Other1 · 2%

Clinical Trials

Trial Activity

49 trials

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
Recruiting·HHeartWorks, Inc.·Phase 1·NCT05647213·50 enrolled
Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways
Recruiting·AAssistance Publique Hopitaux De Marseille·N/A·NCT02923440·300 enrolled
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Recruiting·LLeiden University Medical Center·N/A·NCT06932081·400 enrolled
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Recruiting·—·Phase 4·NCT06260059·40 enrolled
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Recruiting·—·Phase 3·NCT04217421·236 enrolled
Impact of a Neuro-cardiac Rehabilitation Program on the Quality of Life of Children, Adolescents, and Young Adults With Congenital Heart Disease: the Multicentre Randomized Controlled QUALINEUROREHAB Trial
Recruiting·UUniversity Hospital, Bordeaux·Preclinical·NCT05670132·192 enrolled
PRISM: PRecision Integrated Saturation Monitor A Novel Approach to Monitoring Oxygen Saturation in Children A Prospective, Observational, Comparative Validation Clinical Study to Evaluate the Accuracy of a Novel Abdominal Pulse Oximeter With Integrated Motion Detection and Skin Tone Calibration Against Arterial Blood Gas (SaO₂) Measurements and Conventional Fingertip Pulse Oximetry (SpO₂) in Pediatric Patients.
Recruiting·LLe Bonheur Children's Hospital·N/A·NCT07686341·100 enrolled
The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R): A Global Register to Investigate Factors Associated With Morbidity and Mortality in Adult Patients With Congenital Heart Disease (ACHD) on the Waiting List for Heart or Heart/Lung Transplantation
Recruiting·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT04848844·2,000 enrolled
Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)
Active, not recruiting·—·Phase 1·NCT04236479·17 enrolled
Procedural Pain Management by Multimodal Sedation Analgesia Combining Hypnosis in Children With Congenital Heart Disease
Not yet recruiting·FFondation Hôpital Saint-Joseph·N/A·NCT06373627·104 enrolled
Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease
Not yet recruiting·UUniversity Medical Centre Ljubljana·Phase 4·NCT07354880·30 enrolled
Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)
Not yet recruiting·TThe University of Hong Kong·N/A·NCT07663799·20 enrolled
The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease
Completed·UUniversitas Sumatera Utara·Phase 1·NCT06298344·86 enrolled
Hybrid Closure of Congenital Heart Disease
Completed·NNanjing Medical University·N/A·NCT02794584·200 enrolled
Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?
Completed·GGöteborg University·Phase 2·NCT02232399·72 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)